Dr Reddy's Q2 Net Profit Down 9.3%, Revenue Up 16.5% - Business News
By Rediff Money Desk, New Delhi Nov 05, 2024 18:45
Dr Reddy's Laboratories reports a 9.35% decline in Q2 net profit to Rs 1,341.5 crore, while revenue increased 16.51% to Rs 8,016.2 crore. Read more.
New Delhi, Nov 5 (PTI) Pharma major Dr Reddy's Laboratories (DRL) on Tuesday reported a 9.35 per cent decline in its consolidated net profit to Rs 1,341.5 crore for the second quarter ended September 2024.
DRL had posted a net profit of Rs 1,480 crore in the July-September quarter a year ago, according to a regulatory filing from the Hyderabad-based firm.
However, its revenue increased 16.51 per cent to Rs 8,016.2 crore in the September quarter from Rs 6,880.2 crore in the year-ago period.
"Year-on-year growth was primarily driven by growth in global generics revenues. QoQ growth was primarily driven by global generics revenues in emerging markets, India, Europe as well as PSAI," DRL said in its earnings statement.
Its total operating expenses grew 34.3 per cent to Rs 3,021.8 crore in Q2 FY25.
Its Co-Chairman and MD GV Prasad said: "We delivered another good quarter and maintained the growth momentum across businesses. We made progress on our future growth drivers, operationalised our venture with Nestle and completed the acquisition of Nicotinell and related brands".
DRL's revenue from Pharmaceutical Services and Active Ingredients rose 16.76 per cent to Rs 1,103 crore.
Its revenue from the Global Generics segment surged 17.17 per cent to Rs 7,157.6 crore in the September quarter.
This growth "was broad-based, driven by improved sales volumes and new product launches. Sequential growth was primarily driven by emerging markets and Europe", it said.
However, its revenue from the 'Others' segment fell 73.83 per cent to Rs 17.9 crore.
On the outlook, Prasad said: "We will continue to drive efficiency, strengthen our core businesses, and positively impact patient lives through science and innovation".
Shares of Dr Reddy's Laboratories (DRL) on Tuesday settled at Rs 1,272.55 on BSE, up 0.36 per cent from the previous close.
DRL had posted a net profit of Rs 1,480 crore in the July-September quarter a year ago, according to a regulatory filing from the Hyderabad-based firm.
However, its revenue increased 16.51 per cent to Rs 8,016.2 crore in the September quarter from Rs 6,880.2 crore in the year-ago period.
"Year-on-year growth was primarily driven by growth in global generics revenues. QoQ growth was primarily driven by global generics revenues in emerging markets, India, Europe as well as PSAI," DRL said in its earnings statement.
Its total operating expenses grew 34.3 per cent to Rs 3,021.8 crore in Q2 FY25.
Its Co-Chairman and MD GV Prasad said: "We delivered another good quarter and maintained the growth momentum across businesses. We made progress on our future growth drivers, operationalised our venture with Nestle and completed the acquisition of Nicotinell and related brands".
DRL's revenue from Pharmaceutical Services and Active Ingredients rose 16.76 per cent to Rs 1,103 crore.
Its revenue from the Global Generics segment surged 17.17 per cent to Rs 7,157.6 crore in the September quarter.
This growth "was broad-based, driven by improved sales volumes and new product launches. Sequential growth was primarily driven by emerging markets and Europe", it said.
However, its revenue from the 'Others' segment fell 73.83 per cent to Rs 17.9 crore.
On the outlook, Prasad said: "We will continue to drive efficiency, strengthen our core businesses, and positively impact patient lives through science and innovation".
Shares of Dr Reddy's Laboratories (DRL) on Tuesday settled at Rs 1,272.55 on BSE, up 0.36 per cent from the previous close.
Source: PTI
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 8.36 ( -0.12)
- 56233421
- Srestha Finvest
- 0.60 (+ 3.45)
- 40360444
- Standard Capital
- 0.99 ( -1.00)
- 23259568
- AvanceTechnologies
- 0.92 ( 0.00)
- 16468235
- Gujarat Natural Res
- 24.73 (+ 4.13)
- 12245243
MORE NEWS
Bihar Food Processing Investors' Meet: Chirag...
Bihar hosts a food processing investor meet on December 2nd, showcasing its potential...
India's Coal Production Rises 7.2% in November
India's coal production increased by 7.2% in November 2024 to 90.62 million tonnes,...
Petrol & Diesel Sales Surge on Festive Demand
India's petrol and diesel consumption rebounded in November, driven by festive season...